Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/27/2025

GLP-1 Receptor Agonist Eligibility Assessment

Current FDA-Approved Indications and Guidelines

  • The American Diabetes Association recommends GLP-1 receptor agonists for weight management in patients with a BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, with a strength of evidence of high quality 1, 2
  • For patients with type 2 diabetes, GLP-1 receptor agonists are recommended as an adjunct to diet and exercise to improve glycemic control, with a strength of evidence of high quality 3, 4
  • The American Heart Association recommends GLP-1 receptor agonists for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, with a strength of evidence of moderate quality 3, 4

BMI-Based Treatment Thresholds from Guidelines

  • For patients with a BMI <30 kg/m², DPP-4 inhibitors and SGLT2 inhibitors are preferred over GLP-1 RAs for patients with diabetes, with a strength of evidence of moderate quality 3, 4
  • For patients with a BMI 30-35 kg/m², GLP-1 RAs and SGLT2 inhibitors are considered equally good options, with GLP-1 RAs offering greater weight loss, with a strength of evidence of moderate quality 3, 4
  • For patients with a BMI >35 kg/m², GLP-1 RAs constitute the second-line drug of choice for patients with diabetes, with a strength of evidence of moderate quality 3, 5

Evaluation of Comorbidities and Eligibility

  • Patients with hypothyroidism do not qualify for GLP-1 RA use at a BMI of 25.4, as it is not a weight-related comorbidity, with a strength of evidence of low quality 1, 2
  • Patients would qualify for a GLP-1 RA if they develop type 2 diabetes mellitus, or if their BMI increases to ≥27 kg/m² with comorbidities or ≥30 kg/m² without comorbidities, with a strength of evidence of moderate quality 1, 2, 3, 4